Robert E. Landry, EVP Finance CFO at REGENERON PHARMACEUTICALS, INC. (REGN), sold 4,949 shares at $821.40 ($4.1M) on 2023-03-28, disclosed to the SEC on 2023-03-29.
Scheduled sale ($4.1M) by EVP Finance CFO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $819.47 | 39 | $32K | 0.8% |
| 2 | $820.46 | 50 | $41K | 1.0% |
| 3 | $821.39 | 48 | $39K | 1.0% |
| 4 | $822.57 | 18 | $15K | 0.4% |
| 5 | $824.30 | 4 | $3K | 0.1% |
| 6 | $825.17 | 589 |
| $486K |
| 11.9% |
| 7 | $825.17 | 2,204 | $1.8M | 44.6% |
| 8 | $825.59 | 13 | $11K | 0.3% |
| 9 | $829.16 | 4 | $3K | 0.1% |
| 10 | $830.01 | 7 | $6K | 0.1% |
| 11 | $818.81 | 10 | $8K | 0.2% |
| 12 | $820.85 | 115 | $94K | 2.3% |
| 13 | $820.85 | 115 | $94K | 2.3% |
| 14 | $821.40 | 142 | $117K | 2.9% |
| 15 | $821.40 | 142 | $117K | 2.9% |
| 16 | $822.67 | 128 | $105K | 2.6% |
| 17 | $822.67 | 128 | $105K | 2.6% |
| 18 | $823.60 | 181 | $149K | 3.7% |
| 19 | $823.60 | 181 | $149K | 3.7% |
| 20 | $824.54 | 157 | $129K | 3.2% |
| 21 | $824.54 | 157 | $129K | 3.2% |
| 22 | $825.37 | 243 | $201K | 4.9% |
| 23 | $825.37 | 243 | $201K | 4.9% |
| 24 | $826.36 | 31 | $26K | 0.6% |
| Total | $824.36 avg | 4,949 | $4.1M | 100% |
| Filing → |
| REGN | SELL | 2023-08-25 | $188K | — | Filing → |
| REGN | SELL | 2023-02-07 | $2.1M | — | Filing → |
| REGN | SELL | 2022-12-02 | $462K | — | Filing → |